H. Lundbeck A/S (HLUBF)

OTCMKTS · Delayed Price · Currency is USD
5.25
0.00 (0.00%)
Dec 12, 2024, 4:00 PM EST
20.69%
Market Cap 5.65B
Revenue (ttm) 3.21B
Net Income (ttm) 401.88M
Shares Out n/a
EPS (ttm) 0.41
PE Ratio 14.06
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open 5.25
Previous Close 5.25
Day's Range 5.25 - 5.25
52-Week Range 3.91 - 6.65
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 5, 2025

About H. Lundbeck

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat M... [Read more]

Sector Healthcare
Founded 1951
Employees 5,681
Stock Exchange OTCMKTS
Ticker Symbol HLUBF
Full Company Profile

Financial Performance

In 2023, H. Lundbeck's revenue was 19.91 billion, an increase of 9.13% compared to the previous year's 18.25 billion. Earnings were 2.29 billion, an increase of 19.52%.

Financial numbers in DKK Financial Statements

News

NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining around 150 points on Monday. Shares of NVIDIA Corporation (NASDAQ: NVDA) rose during Monday’s trading session. A government-backed think tank...

2 months ago - Benzinga

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record

Lundbeck announced Monday it would buy Longboard Pharmaceuticals in a $2.6 billion deal that sent Longboard stock to a record high.

2 months ago - Investor's Business Daily

Longboard Pharmaceuticals’ stock soars amid Lundbeck’s $2.6 billion deal to acquire the company

H. Lundbeck plans to acquire Longboard Pharmaceuticals in a $2.6 billion deal, the companies announced Monday.

2 months ago - MarketWatch

Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion

Lundbeck to Acquire Longboard Pharmaceuticals (LBPH) for $2.6 Billion

2 months ago - GuruFocus

Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?

H. Lundbeck acquires Longboard Pharmaceuticals for $2.6 billion. ... Full story available on Benzinga.com

2 months ago - Benzinga

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 47%; Here Are 20 Stocks Moving Premarket

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply in today's pre-market trading . Lundbeck agreed to acquire Longboard Pharmaceuticals in a transaction valued at approximately $2....

2 months ago - Benzinga

Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal

Danish pharmaceutical company H. Lundbeck A/S has agreed to acquire Longboard Pharmaceuticals Inc in a deal with an equity value of $2.6 billion.

2 months ago - BNN Bloomberg